China NMPA Drug Inspection - Hubei Qianjiang Pharmaceutical Co., Ltd. - Goose does not eat grass

This National Medical Products Administration (NMPA) announcement, published on October 31, 2019, details regulatory actions taken against two entities for issues involving unqualified Traditional Chinese Medicine materials. The first case concerned Ezhou Central Hospital, which on July 21, 2016, was found to be using substandard *Centipeda minima* (batch number 150401), supplied by Anhui People's Traditional Chinese Medicine Pieces Co., Ltd. The product contained impurities exceeding permitted levels, violating Article 49 of the Drug Administration Law. The Ezhou Municipal Food and Drug Administration imposed a fine and confiscated illegal gains totaling RMB 135.8. The second case involved Hubei Tianxiaming Pharmaceutical Co., Ltd., which on July 7, 2016, sold substandard *Centipeda minima* (batch number 150701), from Anhui Yishengyuan Traditional Chinese Medicine Pieces Technology Co., Ltd. This material also had impurities beyond regulatory limits, violating Article 49 of the Drug Administration Law. The Wuhan Municipal Food and Drug Administration issued an administrative penalty of RMB 330. These actions highlight strict enforcement of drug quality standards under China's drug administration laws.